Telix Pharmaceuticals Ltd — Capital/Financing Update 2020

Dec 16, 2020

Telix Pharmaceuticals Limited Suite 401, 55 Flemington Road North Melbourne, VIC, 3051 Australia www.telixpharma.com ACN: 616 620 369

==> picture [143 x 79] intentionally omitted <==

17 December 2020

Notice under section 708A Corporations Act

Telix Pharmaceuticals Limited (ASX Code: TLX) (“Company”)

Reference is made to the Appendix 2A released on 17 December 2020 and the issue of fully paid ordinary shares in Telix Pharmaceuticals Limited (“Shares”). For the purposes of section 708A(5)(e) of the Corporations Act, the Company gives notice that:

• (a) the Company issued 151,149 Shares upon the exercise of 200,000 options under the code TLXO002

• (b) Telix issued the shares without disclosure under part 6D.2 of the Corporations Act;

• (c) as at the date of this notice the Company has complied with the provisions of Chapter 2M of the Corporations Act as they apply to the Company and section 674 of the Corporations Act; and

• (d) as at the date of this notice there is no information which is “excluded information” (as defined in section 708A(7) of the Corporations Act) which is required to be disclosed by the Company.

For and on behalf of the Board of Telix Pharmaceuticals Limited

==> picture [104 x 35] intentionally omitted <==

Melanie Farris Company Secretary